In the Claims

1-62 (Canceled).

63 (currently amended). An isolated polypeptide comprising an amino acid sequence, said amino acid sequence having at least 95% identity to the full length of ~~that has at least 95% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

64 (previously presented). The isolated polypeptide according to claim 63, wherein said polypeptide comprises SEQ ID NO: 100.

65 (previously presented). The isolated polypeptide according to claim 63, wherein said polypeptide consists of SEQ ID NO: 100.

66 (currently amended). The isolated polypeptide according to claim 63, wherein said amino acid sequence has at least 96% identity to the full length of ~~polypeptide has at least 96% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

67 (currently amended). The isolated polypeptide according to claim 63, wherein said amino acid sequence has at least 97% identity to the full length of ~~polypeptide has at least 97% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

68 (currently amended). The isolated polypeptide according to claim 63, wherein said amino acid sequence has at least 98% identity to the full length of ~~polypeptide has at least 98% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

69 (currently amended). The isolated polypeptide according to claim 63, wherein said amino acid sequence has at least 99% identity to the full length of ~~polypeptide has at least 99%identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

70 (currently amended). A composition comprising a carrier and a polypeptide comprising an amino acid sequence, said amino acid sequence having at least 95% identity to the full length of ~~that has at least 95% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

71 (previously presented). The composition according to claim 70, wherein said polypeptide comprises SEQ ID NO: 100.

72 (previously presented). The composition according to claim 70, wherein said polypeptide consists of SEQ ID NO: 100.

73 (currently amended). The composition according to claim 70, wherein said amino acid sequence has at least 96% identity to the full length of ~~polypeptide has at least 96% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

74 (currently amended). The composition according to claim 70, wherein said amino acid sequence has at least 97% identity to the full length of ~~polypeptide has at least 97% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

75 (currently amended). The composition according to claim 70, wherein said amino acid sequence has at least 98% identity to the full length of ~~polypeptide has at least 98% identity to~~

SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

76 (currently amended). The composition according to claim 70, wherein said amino acid sequence has at least 99% identity to the full length of ~~polypeptide has at least 99% identity to~~ SEQ ID NO: 100 and wherein said polypeptide has kinase activity or activates the MAP kinase pathway.

77 (previously presented). The composition according to claim 70, wherein said carrier is a pharmaceutical carrier.

78 (previously presented). The composition according to claim 70, wherein said carrier is an adjuvant.